Skip to main content
Fig. 2 | The Journal of Headache and Pain

Fig. 2

From: Long term safety, tolerability, and efficacy of intracutaneous zolmitriptan (M207) in the acute treatment of migraine

Fig. 2

Key Efficacy Outcomes. a Percentage of headaches for which subjects experienced freedom from headache pain and/or most bothersome other migraine-associated symptom at 2 h post-dose. Results for MBS-freedom are presented only for those whose MBS was present pre-dose. Numbers below bars indicate number of headaches assessed. MBS: Most Bothersome Symptom. b Percentage of headaches for which subjects had sustained pain freedom from 2 to24 hours and from 2 to 48 h post-dose. Numbers below bars indicate number of headaches assessed

Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us